Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia

Blood Cancer Journal

Volumn 5, Issue 4, 2015, Pages

  Eriksson, A ^a   Osterroos A ^a   Hassan, S ^a   Gullbo, J ^a   Rickardson, L ^a   Jarvius, M ^a   Nygren, P ^a   Fryknas M ^a   Hoglund M ^a   Larsson, R ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MEPACRINE;

DRUG EFFECTS; DRUG SCREENING; HL 60 CELL LINE; HUMAN; ISOLATION AND PURIFICATION; LEUKEMIA, MYELOID, ACUTE; MONONUCLEAR CELL; PATHOLOGY;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; QUINACRINE;

EID: 84961530441     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/BCJ.2015.31     Document Type: Article

References (38)

1. Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther 2013; 93: 335–341.
2. Laubenbacher R, Hower V, Jarrah A, Torti SV, Shulaev V, Mendes P et al. A systems biology view of cancer. Biochim Biophys Acta 2009; 1796: 129–139.
3. Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R et al. High-throughput screening: update on practices and success. J Biomol Screen 2006; 11: 864–869.
4. Hart CP. Finding the target after screening the phenotype. Drug Discov Today 2005; 10: 513–519.
5. Dhar S GJ, Nilsson K, Nygren P, Larsson R. A nonclonogenic cytotoxicity assay using primary cultures of patient tumor cells for anticancer drug screening. J Biomol Screen 1998; 3: 207–216.
6. Cree IA, Glaysher S, Harvey AL. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 2010; 10: 375–379.
7. Cree IA. Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol 2009; 21: 39–43.
8. Nygren P, Larsson R. Predictive tests for individualization of pharmacological cancer treatment. Expert Opin Med Diagn 2008; 2: 349–360.
9. Fridborg H, Jonsson E, Nygren P, Larsson R. Relationship between diagnosisspecific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 1999; 35: 424–432.
10. Haglund C, Aleskog A, Nygren P, Gullbo J, Hoglund M, Wickstrom M et al. In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues. Cancer Chemotherapy Pharmacol 2012; 69: 697–707.
11. Gullbo J, Fryknas M, Rickardson L, Darcy P, Hagg M, Wickstrom M et al. Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment. Biochem Pharmacol 2011; 82: 139–147.
12. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50: 177–185.
13. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977; 270: 347–349.
14. Andersson A, Eden P, Lindgren D, Nilsson J, Lassen C, Heldrup J et al. Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia 2005; 19: 1042–1050.
15. Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 1983; 62: 709–721.
16. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885–3891.
17. Rickardson L, Fryknas M, Haglund C, Lovborg H, Nygren P, Gustafsson MG et al. Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol 2006; 58: 749–758.
18. Lindhagen E, Nygren P, Larsson R. The fluorometric microculture cytotoxicity assay. Nat Protoc 2008; 3: 1364–1369.
19. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929–1935.
20. Kupershmidt I, Su QJ, Grewal A, Sundaresh S, Halperin I, Flynn J et al. Ontologybased meta-analysis of global collections of high-throughput public data. PLoS One 2010; 5: e13066.
21. Brennan RJ, Nikolskya T, Bureeva S. Network and pathway analysis of compoundprotein interactions. Methods Mol Biol 2009; 575: 225–247.
22. Harris DW, Kenrick MK, Pither RJ, Anson JG, Jones DA. Development of a highvolume in situ mRNA hybridization assay for the quantification of gene expression utilizing scintillating microplates. Anal Biochem 1996; 243: 249–256.
23. Kelley BP, Lunn MR, Root DE, Flaherty SP, Martino AM, Stockwell BR. A flexible data analysis tool for chemical genetic screens. Chem Biol 2004; 11: 1495–1503.
24. Andrews WJ, Panova T, Normand C, Gadal O, Tikhonova IG, Panov KI. Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription. J Biol Chem 2013; 288: 4567–4582.
25. Bosanquet A, Nygren P, Weisenthal L. Individualized Tumor Response Testing in Leukemia and Lymphoma. In: Innovative Leukemia and Lymphoma Therapy. 1st edn, Informa Healthcare: New York, NY, USA, 2008.
26. Ehsanian R, Van Waes C, Feller SM. Beyond DNA binding-a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal 2011; 9: 13.
27. Yung L, Huang Y, Lessard P, Legname G, Lin ET, Baldwin M et al. Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis 2004; 4: 53.
28. Gurova K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncol 2009; 5: 1685–1704.
29. Preet R, Mohapatra P, Mohanty S, Sahu SK, Choudhuri T, Wyatt MD et al. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer 2012; 130: 1660–1670.
30. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA. Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 2010; 285: 19162–19172.
31. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005; 102: 17448–17453.
32. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV et al. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 2009; 28: 1151–1161.
33. Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, Gasparian AV et al. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 2009; 8: 3960–3970.
34. Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 1996; 7: 568–578.
35. Quin JE, Devlin JR, Cameron D, Hannan KM, Pearson RB, Hannan RD. Targeting the nucleolus for cancer intervention. Biochim Biophys Acta 2014; 1842: 802–816.
36. Huff AC, Kreuzer KN. Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases. J Biol Chem 1990; 265: 20496–20505.
37. Pan XN, Chen JJ, Wang LX, Xiao RZ, Liu LL, Fang ZG et al. Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation. PloS One 2014; 9: e105381.
38. Falantes JF, Trujillo P, Piruat JI, Calderon C, Marquez-Malaver FJ, Martin-Antonio B et al. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2015; 15: 236–244.